Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
10 studies found for:    TL32711
Show Display Options
Rank Status Study
1 Recruiting Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
Conditions: Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML)
Interventions: Drug: birinapant;   Drug: Azacitidine;   Drug: Placebo
2 Terminated Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Smac mimetic TL32711;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: biopsy
3 Completed Dose Escalation, Combination Chemotherapy Safety Study of TL32711, in Subjects With Advanced or Metastatic Solid Tumors
Condition: Cancer
Intervention: Drug: TL32711
4 Recruiting Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
Condition: Myelodysplastic Syndrome
Interventions: Drug: TL32711;   Drug: 5-Azacitidine
5 Recruiting Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B
Condition: Hepatitis B
Interventions: Drug: Antiviral Therapy (tenofovir or entecavir);   Drug: Birinapant;   Drug: Placebo (for birinapant)
6 Recruiting Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
Conditions: Relapsed Epithelial Ovarian Cancer;   Relapsed Primary Peritoneal Cancer;   Relapsed Fallopian Tube Cancer
Interventions: Drug: Birinapant;   Drug: Conatumumab
7 Completed Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Condition: Cancer
Intervention: Drug: TL32711
8 Completed Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
Conditions: Epithelial Ovarian Cancer;   Peritoneal Neoplasms;   Fallopian Tube Neoplasms
Intervention: Drug: Birinapant (TL32711)
9 Recruiting A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia
Condition: Acute Myelogenous Leukemia
Intervention: Drug: TL32711
10 Withdrawn 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
Conditions: Ovarian Neoplasms;   Ovarian Cancer;   Fallopian Tube Neoplasms;   Fallopian Tube Cancer
Interventions: Drug: [18F]-CP18;   Procedure: PET/ CT

Indicates status has not been verified in more than two years